PRO ACT
PHARMACY BENEFIT MANAGEMENT

1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

Dilaudid® (hydromorphone) & Exalgo® (hydromorphone extended-release [ER]) Prior Authorization Request Form (Page 1 of 2)

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand** ❑ Check if request is for **continuation of therapy**	Directions for Use:	

Clinical Information (required)

Select the diagnosis below:

❑ Pain [**Dilaudid (hydromorphone)** only]
❑ Severe pain in opioid-tolerant patients requiring a long-term, daily, around-the-clock opioid analgesic and for which other treatment options (e.g., non-opioid analgesics or immediate-release opioids) are inadequate [**Exalgo (Hydromorphone extended release)** only]
❑ Other diagnosis:______________________________ICD-10 Code(s): ______________________________________

If the patient has End-Stage Renal Disease (ESRD), select all that apply:

❑ The medication is being used to treat one of the following: graft site pain or pain medication overdose
❑ The dialysis provider (i.e., nephrologist, nurse practitioner, physician assistant, or dialysis center) receives a monthly capitation payment to manage the ESRD patient's care

Select the medications the patient has a failure, contraindication, or intolerance to:

❑ Codeine sulfate
❑ Embeda
❑ Fentanyl transdermal patch
❑ Hydrocodone-acetaminophen (APAP) 300mg
❑ Hydrocodone-APAP 325mg
❑ Hydrocodone-ibuprofen 5-200mg
❑ Hydrocodone-ibuprofen 7.5-200mg
❑ Hydrocodone-ibuprofen 10-200mg
❑ Hydromorphone ER
❑ Hydromorphone immediate-release (IR)
❑ Hysingla ER
❑ Ibudone
❑ Levorphanol
❑ Lorcet
❑ Lorcet HD
❑ Lorcet Plus
❑ Morphine sulfate ER capsule (generic Avinza)
❑ Morphine sulfate ER capsule (generic Kadian)
❑ Morphine sulfate ER tablet
❑ Morphine sulfate IR
❑ MS Contin
❑ Nucynta
❑ Nucynta ER
❑ Opana ER (crush resistant)
❑ Oxycodone ER
❑ Oxycodone IR
❑ Oxycodone-APAP
❑ Oxycodone-aspirin
❑ Oxycodone-ibuprofen
❑ Oxycontin
❑ Oxymorphone ER
❑ Oxymorphone IR
❑ Primlev
❑ Vicodin
❑ Vicodin ES
❑ Vicodin HP
❑ Xtampza ER
❑ Zamicet
❑ Zohydro ER

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

PRO ACT
PHARMACY BENEFIT MANAGEMENT

1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

Dilaudid® (hydromorphone) & Exalgo® (hydromorphone extended-release [ER]) Prior Authorization Request Form (Page 2 of 2)

Quantity limit requests:
What is the quantity requested per DAY? _______
Does the patient's diagnosis include malignant (cancer) pain? ❑ **Yes** ❑ **No**
Was the medication prescribed by a pain specialist or by pain management consultation? ❑ **Yes** ❑ **No**
Select all of the following that have been maintained and documented in chart notes:
- ❑ A description of the nature and intensity of the pain
- ❑ An appropriate patient medical history and physical examination
- ❑ An updated, comprehensive treatment plan (the treatment plan should state objectives that will be used to determine treatment success, such as pain relief or improved physical and/or psychosocial function)
- ❑ Appropriate dose escalation
- ❑ Ongoing, periodic review of the course of opioid therapy
- ❑ Verification that the risks and benefits of the use of the requested drug have been discussed with the patient, significant other(s), and/or guardian

Chart documentation:
Will chart documentation be submitted to *ProAct®* with this form, confirming the above information? ❑ **Yes** ❑ **No**
***Please note: Chart documentation of the above is required to be submitted for quantity limit requests for this drug.*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

____

____

Please note: This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.

Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): ______________________________ **Date:** ______________

PROACT INTERNAL USE ONLY:					
Clinical Review Decision					
	Approved, through				
	Denied (documentation attached, if necessary)				
Tracking:					
1st Attempt		2nd Attempt		Letter Mailed:	

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
Office use only: Dilaudid-Exalgo-Hydromorphone-HydromorphoneER_Jan_2018